AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
By Sabela Ojea
Shares of AbbVie lost 4.6% to close at $159.62 on Friday after the company warned about the effects of losing the exclusivity of its patent for the arthritis medication Humira, the highest-grossing drug ever.
The drugmaker guided for second-quarter revenue of $14 billion, reflecting a step-up in volume erosion from Humira due to an increase in competition. The second and fourth quarter are usually known for having the highest levels of volume.
The North Chicago, Ill.-based company's full-year outlook is in line with its guidance at the beginning of the year, Chief Commercial Officer Jeffrey Ryan Stewart said on a call with analysts.
"We are not saying that volume is worse than we originally guided. We're saying this is tracking in line with our expectations," Chief Executive Robert Michael said.
In the first quarter, AbbVie reported a 36% drop in Humira-related revenue, driving a 3.9% decline in revenue coming from its immunology portfolio. Despite this, its quarterly topline performance rose from gains elsewhere and the company raised its annual adjusted earnings guidance.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 26, 2024 16:53 ET (20:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?